ReviewNature reviews. Immunology2010
Surrogate end points in the design of immunotherapy trials: emerging lessons from type 1 diabetes.
Review in Nature reviews. Immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Dawn of Monitoring Regulatory T Cells in (Pre-)clinical Studies: Their Relevance Is Slowly Recognised.Frontiers in medicine · 2020Pooled it
- Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group.Clinical and experimental immunology · 2010Guideline
- First-in-human, double-blind, randomized phase 1b study of peptide immunotherapy IMCY-0098 in new-onset type 1 diabetes.BMC medicine · 2023Trial
- Trial
- Prioritizing Early Disease Intervention.Therapeutic innovation & regulatory science · 2023Article
- The need and benefit of immune monitoring to define patient and disease heterogeneity, mechanisms of therapeutic action and efficacy of intervention therapy for precision medicine in type 1 diabetes.Frontiers in immunology · 2023Article
- Interval design to identify the optimal biological dose for immunotherapy.Contemporary clinical trials communications · 2022Article
- The parasite-derived peptide FhHDM-1 activates the PI3K/Akt pathway to prevent cytokine-induced apoptosis of β-cells.Journal of molecular medicine (Berlin, Germany) · 2021Article
- The β Cell in Diabetes: Integrating Biomarkers With Functional Measures.Endocrine reviews · 2021Review
- Characterization of Proinsulin T Cell Epitopes Restricted by Type 1 Diabetes-Associated HLA Class II Molecules.Journal of immunology (Baltimore, Md. : 1950) · 2020Article
- Review
- Proinsulin C-peptide is an autoantigen in people with type 1 diabetes.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Combinatorial detection of autoreactive CD8Diabetologia · 2018Article
- Article
- Human islets and dendritic cells generate post-translationally modified islet autoantigens.Clinical and experimental immunology · 2016Article
- Proinsulin multi-peptide immunotherapy induces antigen-specific regulatory T cells and limits autoimmunity in a humanized model.Clinical and experimental immunology · 2015Article
- Immune biomarkers: the promises and pitfalls of personalized medicine.Nature reviews. Immunology · 2015Review
- Article
- Immune modulation in humans: implications for type 1 diabetes mellitus.Nature reviews. Endocrinology · 2014Review
- Progress in immune-based therapies for type 1 diabetes.Clinical and experimental immunology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Approximately 5% of people in developed countries suffer from 1 of approximately 80 classified autoimmune diseases. The sheer scale of the clinical problem captures the interests of health policy makers, academics, funding bodies and pharmaceutical companies in equal measure. In recent decades, immunologists have gained a good understanding of disease pathogenesis, which has led to the development of various potential therapies. The next challenge is to establish which therapies have superior efficacy, sustainability and safety. Therapeutic trials that depend on clinical end points are long lasting and expensive. In this Opinion article we offer a perspective on the future of clinical trial design in which the process is significantly shortened by making greater use of laboratory measures to determine therapeutic outcome.
Indexed as
Identifiers
20098462What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.